Clinical and angiographic outcomes of the first Korean-made sirolimus-eluting coronary stent with abluminal bioresorbable polymer

Hyoung Mo Yang, Kyoung Woo Seo, Junghan Yoon, Hyo Soo Kim, Kiyuk Chang, Hong Seok Lim, Byoung Joo Choi, So Yeon Choi, Myeong Ho Yoon, Seung Hwan Lee, Sung Gyun Ahn, Young Jin Youn, Jun Won Lee, Bon Kwon Koo, Kyung Woo Park, Han Mo Yang, Jung Kyu Han, Ki Bae Seung, Wook Sung Chung, Pum Joon KimYoon Seok Koh, Hun Jun Park, Seung Jea Tahk

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)


Background and Objectives: This trial evaluated the safety and efficacy of the Genoss drug-eluting coronary stent. Methods: This study was a prospective, multicenter, randomized trial with a 1:1 ratio of Genoss drug-eluting stent (DES)™ and Promus Element™. Inclusion criteria were the presence of stable angina, unstable angina, or silent ischemia. Angiographic inclusion criteria were de novo coronary stenotic lesion with diameter stenosis >50%, reference vessel diameter of 2.5-4.0 mm, and lesion length ≤40 mm. The primary endpoint was in-stent late lumen loss at 9-month quantitative coronary angiography follow-up. Secondary endpoints were in-segment late lumen loss, binary restenosis rate, death, myocardial infarction (MI), target lesion revascularization (TLR), target vessel revascularization (TVR), and stent thrombosis during 9 months of follow-up. Results: We enrolled 38 patients for the Genoss DES™ group and 39 patients for the Promus Element™ group. In-stent late lumen loss at 9 months was not significantly different between the 2 groups (0.11±0.25 vs. 0.16±0.43 mm, p=0.567). There was no MI or stent thrombosis in either group. The rates of death (2.6% vs. 0%, p=0.494), TLR (2.6% vs. 2.6%, p=1.000), and TVR (7.9% vs. 2.6%, p=0.358) at 9 months were not significantly different. Conclusion: This first-in-patient study of the Genoss DES™ stent showed excellent angiographic outcomes for in-stent late lumen loss and major adverse cardiac events over a 9-month follow-up.

Original languageEnglish
Pages (from-to)898-906
Number of pages9
JournalKorean Circulation Journal
Issue number6
Publication statusPublished - 2017 Nov

Bibliographical note

Funding Information:
This study was supported by Genoss Company Limited (Suwon, Korea).

Publisher Copyright:
© 2017. The Korean Society of Cardiology.

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Clinical and angiographic outcomes of the first Korean-made sirolimus-eluting coronary stent with abluminal bioresorbable polymer'. Together they form a unique fingerprint.

Cite this